NASDAQ:FEMY Femasys (FEMY) Stock Price, News & Analysis $1.11 +0.01 (+0.91%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.1150-Day Range$0.96▼$1.4252-Week Range$0.25▼$4.75Volume93,774 shsAverage Volume200,025 shsMarket Capitalization$24.66 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Femasys alerts: Email Address Femasys MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside951.1% Upside$11.67 Price TargetShort InterestHealthy3.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.72) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 starsMedical Sector305th out of 879 stocksSurgical & Medical Instruments Industry38th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingFemasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFemasys has only been the subject of 1 research reports in the past 90 days.Read more about Femasys' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.78% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Femasys has recently decreased by 6.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFemasys does not currently pay a dividend.Dividend GrowthFemasys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FEMY. Previous Next 2.2 News and Social Media Coverage News SentimentFemasys has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Femasys this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Femasys insiders have not sold or bought any company stock.Percentage Held by Insiders12.32% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Femasys' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Femasys are expected to grow in the coming year, from ($0.72) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Femasys is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Femasys is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFemasys has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Femasys' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Femasys Stock (NASDAQ:FEMY)Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Read More FEMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FEMY Stock News HeadlinesJuly 4 at 9:04 AM | americanbankingnews.comFemasys Inc. (NASDAQ:FEMY) Short Interest UpdateJune 27, 2024 | globenewswire.comFemasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in AmsterdamJuly 6, 2024 | The Freeport Society (Ad)Biden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.June 27, 2024 | americanbankingnews.comFemasys (NASDAQ:FEMY) versus Intelligent Bio Solutions (NASDAQ:INBS) Head-To-Head ContrastMay 17, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot InitiativeMay 17, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot InitiativeMay 16, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy CouncilMay 16, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy CouncilJuly 6, 2024 | The Freeport Society (Ad)Biden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.May 11, 2024 | markets.businessinsider.comFemasys’s Buy Rating Affirmed by Analyst Jason McCarthy on FemaSeed’s Market Success and Robust Clinical TrialsMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)May 9, 2024 | investorplace.comFEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comFemasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate UpdateMay 7, 2024 | globenewswire.comFemasys Expands Commercial Management Team with Addition of Experienced New HiresApril 18, 2024 | finance.yahoo.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare InitiativesApril 18, 2024 | globenewswire.comFemasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare InitiativesApril 17, 2024 | msn.comFemasys (FEMY) Price Target Increased by 5.41% to 9.95March 31, 2024 | finance.yahoo.comFemasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagSee More Headlines Receive FEMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/06/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:FEMY CUSIPN/A CIK1339005 Webwww.femasys.com Phone770-500-3910FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$13.00 Low Stock Price Target$10.00 Potential Upside/Downside+951.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,250,000.00 Net Margins-1,420.59% Pretax Margin-1,420.11% Return on Equity-104.06% Return on Assets-73.32% Debt Debt-to-Equity Ratio0.29 Current Ratio8.43 Quick Ratio8.02 Sales & Book Value Annual Sales$1.07 million Price / Sales23.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book1.31Miscellaneous Outstanding Shares22,220,000Free Float19,483,000Market Cap$24.66 million OptionableNot Optionable Beta-2.81 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Kathy Lee-Sepsick M.B.A. (Age 56)Founder, President, CEO & Director Comp: $804.67kMr. Dov Elefant (Age 57)Chief Financial Officer Comp: $595.14kMr. Daniel Scott Currie (Age 60)COO, Senior VP & Secretary Comp: $548.15kMs. Mary An Merchant J.D.Ph.D., Vice President of Counsel & Intellectual PropertyDr. Jeffrey Marcus M.D.M.S., Chief Medical AdvisorMs. Christine Thomas (Age 51)Senior VP of Regulatory & Clinical Affairs Dr. James H. Liu M.D.Chief Medical OfficerMr. Richard Spector (Age 53)Chief Commercial Officer More ExecutivesKey CompetitorsPrecision OpticsNASDAQ:POCIBlueRiver AcquisitionNYSE:BLUABrainsWayNASDAQ:BWAYHealth Sciences Acquisitions Co. 2NASDAQ:HSAQSensus HealthcareNASDAQ:SRTSView All CompetitorsInstitutional OwnershipCM Management LLCSold 50,000 shares on 5/14/2024Ownership: 1.800%Clear Creek Financial Management LLCBought 72,505 shares on 4/26/2024Ownership: 1.399%View All Institutional Transactions FEMY Stock Analysis - Frequently Asked Questions How have FEMY shares performed this year? Femasys' stock was trading at $0.9750 at the start of the year. Since then, FEMY stock has increased by 13.8% and is now trading at $1.11. View the best growth stocks for 2024 here. How were Femasys' earnings last quarter? Femasys Inc. (NASDAQ:FEMY) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.05. The company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.30 million. Femasys had a negative net margin of 1,420.59% and a negative trailing twelve-month return on equity of 104.06%. When did Femasys IPO? Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO. How do I buy shares of Femasys? Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FEMY) was last updated on 7/6/2024 by MarketBeat.com Staff From Our PartnersWhy Conservative Americans Are Turning to Gold in 2024Welcome to the financial rollercoaster of 2024, where inflation is relentless, stock markets are inflated, and...All American Assets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBill Gates is all about this tiny $2 stockWhat does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthles...Timothy Sykes | Sponsored"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FEMY Stock Alerts